Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3471751,plasma half-lives,The mean plasma half-lives of enoxacin and the oxo-metabolite were 6.1 h and 6.7 h respectively.,The pharmacokinetics of enoxacin in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471751/),h,6.1,6191,DB00467,Enoxacin
,3471751,plasma half-lives,The mean plasma half-lives of enoxacin and the oxo-metabolite were 6.1 h and 6.7 h respectively.,The pharmacokinetics of enoxacin in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471751/),h,6.7,6192,DB00467,Enoxacin
,3216037,tmax,"Enoxacin was absorbed rapidly, with tmax values ranging from 0.5 to 2.5 hours.",The absorption and disposition of enoxacin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216037/),h,0.5 to 2.5,13831,DB00467,Enoxacin
,3216037,terminal half-life,The terminal half-life ranged from 4.2 to 6.8 hours and the unbound fraction in plasma was 0.33 +/- 0.07.,The absorption and disposition of enoxacin in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216037/),h,4.2 to 6.8,13832,DB00467,Enoxacin
,3216037,unbound fraction in plasma,The terminal half-life ranged from 4.2 to 6.8 hours and the unbound fraction in plasma was 0.33 +/- 0.07.,The absorption and disposition of enoxacin in healthy subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216037/),,0.33,13833,DB00467,Enoxacin
,3216037,Renal clearance,"Renal clearance of enoxacin was 230 +/- 92 mL/min, with 17 +/- 8% of this being due to glomerular filtration and 83 +/- 8% being due to tubular secretion.",The absorption and disposition of enoxacin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216037/),[ml] / [min],230,13834,DB00467,Enoxacin
,6238932,peak serum level,The mean peak serum level of enoxacin was 3.7 mg/l and attained at a mean time of 1.9 h after administration; the mean peak serum level of norfloxacin was 1.45 mg/l at a mean time of 1.5 h.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],3.7,14886,DB00467,Enoxacin
,6238932,peak serum level,The mean peak serum level of enoxacin was 3.7 mg/l and attained at a mean time of 1.9 h after administration; the mean peak serum level of norfloxacin was 1.45 mg/l at a mean time of 1.5 h.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],1.45,14887,DB00467,Enoxacin
,6238932,serum half-lives,The mean serum half-lives were 6.2 h for enoxacin and 3.25 h for norfloxacin.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),h,6.2,14888,DB00467,Enoxacin
,6238932,serum half-lives,The mean serum half-lives were 6.2 h for enoxacin and 3.25 h for norfloxacin.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),h,3.25,14889,DB00467,Enoxacin
,6238932,maximum levels,Both agents penetrated blister fluid well and reached maximum levels of 2.9 mg/l (for enoxacin) and 1.0 mg/l (for norfloxacin).,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],2.9,14890,DB00467,Enoxacin
,6238932,maximum levels,Both agents penetrated blister fluid well and reached maximum levels of 2.9 mg/l (for enoxacin) and 1.0 mg/l (for norfloxacin).,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],1.0,14891,DB00467,Enoxacin
,6238932,urinary recovery,The 24 h urinary recovery of enoxacin of 61% was about twice that of norfloxacin.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),%,61,14892,DB00467,Enoxacin
,1664467,Total body clearance (CLT),"Total body clearance (CLT) of DPP was 1.77 L/h/kg, which was sevenfold greater than that of PXP (0.26 L/h/kg).",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],1.77,15035,DB00467,Enoxacin
,1664467,Total body clearance (CLT),"Total body clearance (CLT) of DPP was 1.77 L/h/kg, which was sevenfold greater than that of PXP (0.26 L/h/kg).",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],0.26,15036,DB00467,Enoxacin
,1664467,renal clearance (CLR),"The DPP renal clearance (CLR) was 1.75 L/h/kg, approximately 13-fold the CLR for PXP (0.13 L/h/kg) and sevenfold the rat glomerular filtration rate.",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],1.75,15037,DB00467,Enoxacin
,1664467,CLR,"The DPP renal clearance (CLR) was 1.75 L/h/kg, approximately 13-fold the CLR for PXP (0.13 L/h/kg) and sevenfold the rat glomerular filtration rate.",Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664467/),[l] / [h·kg],0.13,15038,DB00467,Enoxacin
,6389476,half-life,Plasma assays demonstrated rapid absorption of enoxacin with first-order elimination and a half-life averaging 3.4-6.4 h.,The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389476/),h,3.4-6.4,17366,DB00467,Enoxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,1,38429,DB00467,Enoxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.1,38430,DB00467,Enoxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,3.1,38431,DB00467,Enoxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,1,38432,DB00467,Enoxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.0,38433,DB00467,Enoxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.9,38434,DB00467,Enoxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.2,39031,DB00467,Enoxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.71,39032,DB00467,Enoxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.17,39033,DB00467,Enoxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.48,39034,DB00467,Enoxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],4.6,39035,DB00467,Enoxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],15,39036,DB00467,Enoxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],17.9,39037,DB00467,Enoxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],19.7,39038,DB00467,Enoxacin
,1601962,limit of detection,Determination was possible for ofloxacin over the concentration range 50-2000 ng/ml; the limit of detection was 20 ng/ml.,Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601962/),[ng] / [ml],20,41000,DB00467,Enoxacin
,1601962,recovery,The recovery of ofloxacin added to serum was 88.8-101.7% with a coefficient of variation of less than 5.2%.,Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601962/),%,88.8-101.7,41001,DB00467,Enoxacin
,3162809,elimination half-life,"Drug elimination half-life (mean 4.3 h, s.d. 2.1) was similar to that reported in healthy volunteers.",Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162809/),h,4.3,41488,DB00467,Enoxacin
,3481328,peak serum concentration,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),[mg] / [l],5.5,41593,DB00467,Enoxacin
,3481328,renal excretion during 24 hours,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),%,41,41594,DB00467,Enoxacin
,3309815,Bronchial concentrations,Bronchial concentrations exceed blood levels (mean 3.06 mg/l at 3rd hour).,"[Diffusion, in the bronchial mucus, of enoxacin administered by oral route in man]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3309815/),,3.06,41971,DB00467,Enoxacin
,2453683,tissue-to-serum ratio,"per l., respectively, with a mean tissue-to-serum ratio of 2.53 +/- 1.8.",A double-blind comparative trial of short-term orally administered enoxacin in the prevention of urinary infection after elective transurethral prostatectomy: a clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453683/),,2.53,42288,DB00467,Enoxacin
,3466562,plasma concentration,"The mean (SD) bronchial mucosal concentration for all patients was 117.0 (47.8) micrograms/g, the mean (SD) plasma concentration was 3.1 (1.1) micrograms/ml, and the mean (SD) ratio was 46.8 (45.9).",Penetration of enoxacin into human bronchial mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3466562/),[μg] / [ml],3.1,42470,DB00467,Enoxacin
,7784342,steady-state plasma concentrations,"The effects of norfloxacin (NOR), at steady-state plasma concentrations of 0-32 mg.l-1, on the plasma clearance of a 6 mg.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),[mg] / [l],0-32,45925,DB00467,Enoxacin
,7784342,Ki,"The effects were characterised by a Ki value (Ki = 12 microM), which was comparable with Ki values obtained previously under identical conditions for ciprofloxacin, but higher than that obtained for enoxacin.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),μM,12,45926,DB00467,Enoxacin
,12579941,detection limit,The chemiluminescence intensity was linearly related to the concentration of ENX in the range of 2.0 x 10(-9)-6.0 x 10(-8) mol.L-1 with a detection limit of 4.0 x 10(-10) mol.L-1.,[Terbium sensitized chemiluminescence of enoxacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579941/),[mol] / [l],4.0 x 10(-10),49294,DB00467,Enoxacin
,20662110,flow rate,"A mobile phase solvent consisting of 20 mm sodium dihydrogenphosphate (pH 3.0) and acetonitrile (85:15, v/v) was pumped at a flow rate of 1.0 mL/min.",A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662110/),[ml] / [min],1.0,52340,DB00467,Enoxacin
,8540722,Excretory fluid/plasma area under the concentration-time curve ratios,"Excretory fluid/plasma area under the concentration-time curve ratios were found to be 1.67 +/- 0.36 for nasal secretions, 0.76 +/- 0.28 for saliva, 0.25 +/- 0.07 for sweat, and 0.23 +/- 0.11 for tears.",Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540722/),,1.67,53441,DB00467,Enoxacin
,8540722,Excretory fluid/plasma area under the concentration-time curve ratios,"Excretory fluid/plasma area under the concentration-time curve ratios were found to be 1.67 +/- 0.36 for nasal secretions, 0.76 +/- 0.28 for saliva, 0.25 +/- 0.07 for sweat, and 0.23 +/- 0.11 for tears.",Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540722/),,0.76,53442,DB00467,Enoxacin
,8540722,Excretory fluid/plasma area under the concentration-time curve ratios,"Excretory fluid/plasma area under the concentration-time curve ratios were found to be 1.67 +/- 0.36 for nasal secretions, 0.76 +/- 0.28 for saliva, 0.25 +/- 0.07 for sweat, and 0.23 +/- 0.11 for tears.",Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540722/),,0.25,53443,DB00467,Enoxacin
,8540722,Excretory fluid/plasma area under the concentration-time curve ratios,"Excretory fluid/plasma area under the concentration-time curve ratios were found to be 1.67 +/- 0.36 for nasal secretions, 0.76 +/- 0.28 for saliva, 0.25 +/- 0.07 for sweat, and 0.23 +/- 0.11 for tears.",Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540722/),,0.23,53444,DB00467,Enoxacin
,8540722,elimination half-life,The elimination half-life of enoxacin from sweat (8.27 +/- 2.63 h) was significantly longer than that for plasma (5.10 +/- 0.46 h).,Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540722/),h,8.27,53445,DB00467,Enoxacin
,8540722,elimination half-life,The elimination half-life of enoxacin from sweat (8.27 +/- 2.63 h) was significantly longer than that for plasma (5.10 +/- 0.46 h).,Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540722/),h,5.10,53446,DB00467,Enoxacin
,2653697,t1/2,"The t1/2 for enoxacin ranges from 4 to 6 hours, which allows effective twice-daily administration without significant accumulation.",Enoxacin absorption and elimination characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653697/),h,4 to 6,54494,DB00467,Enoxacin
,3162903,trough level,"At steady state the mean trough level of enoxacin in sputum was 1.75 +/- 0.70 mg/kg (mean +/- S.D.), and the corresponding level in plasma was 1.23 +/- 0.32 mg/l.",Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),[mg] / [kg],1.75,58355,DB00467,Enoxacin
,3162903,trough level,"At steady state the mean trough level of enoxacin in sputum was 1.75 +/- 0.70 mg/kg (mean +/- S.D.), and the corresponding level in plasma was 1.23 +/- 0.32 mg/l.",Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),[mg] / [l],1.23,58356,DB00467,Enoxacin
,3162903,peak sputum concentration at steady state,The mean peak sputum concentration at steady state was 7.12 +/- 4.21 mg/kg with the corresponding level in plasma being 4.54 +/- 1.34 mg/l.,Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),[mg] / [kg],7.12,58357,DB00467,Enoxacin
,3162903,peak sputum concentration at steady state,The mean peak sputum concentration at steady state was 7.12 +/- 4.21 mg/kg with the corresponding level in plasma being 4.54 +/- 1.34 mg/l.,Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),[mg] / [l],4.54,58358,DB00467,Enoxacin
,3162903,times to reach peak concentration (T-max),"The pharmacokinetics of enoxacin in sputum were similar to those in plasma, the only significant difference being between the mean times to reach peak concentration (T-max) which were 2.62 +/- 1.04 and 0.92 +/- 0.44 h in sputum and plasma respectively (P less than 0.01).",Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),h,2.62,58359,DB00467,Enoxacin
,3162903,times to reach peak concentration (T-max),"The pharmacokinetics of enoxacin in sputum were similar to those in plasma, the only significant difference being between the mean times to reach peak concentration (T-max) which were 2.62 +/- 1.04 and 0.92 +/- 0.44 h in sputum and plasma respectively (P less than 0.01).",Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),h,0.92,58360,DB00467,Enoxacin
,3162903,area under the plasma time-concentration curve (AUC) from 0 to 12 h,"After reaching steady state, the mean area under the plasma time-concentration curve (AUC) from 0 to 12 h (the dosing interval) was 26.6 +/- 5.9 mg/h/l, and the mean AUC (0-12) for sputum was 40.9 +/- 21.8 mg/h/kg.",Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),[mg] / [h·l],26.6,58361,DB00467,Enoxacin
,3162903,AUC (0-12),"After reaching steady state, the mean area under the plasma time-concentration curve (AUC) from 0 to 12 h (the dosing interval) was 26.6 +/- 5.9 mg/h/l, and the mean AUC (0-12) for sputum was 40.9 +/- 21.8 mg/h/kg.",Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),[mg] / [h·kg],40.9,58362,DB00467,Enoxacin
,3162903,apparent total clearance,The mean apparent total clearance was 259.6 +/- 48.8 ml/min and the mean apparent volume of distribution was 169.6 +/- 30.51.,Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),[ml] / [min],259.6,58363,DB00467,Enoxacin
,3162903,apparent volume of distribution,The mean apparent total clearance was 259.6 +/- 48.8 ml/min and the mean apparent volume of distribution was 169.6 +/- 30.51.,Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162903/),,169.6,58364,DB00467,Enoxacin
,9624541,peak concentration,"Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h), followed by ciprofloxacin (237 mg/l) and norfloxacin (157 mg/l) as determined by the HPLC assay.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],237,59410,DB00467,Enoxacin
,9624541,peak concentration,"Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h), followed by ciprofloxacin (237 mg/l) and norfloxacin (157 mg/l) as determined by the HPLC assay.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],157,59411,DB00467,Enoxacin
,9624541,total amount,"The total amount (mean) excreted by the kidneys as parent drugs were as follows: enoxacin 54% of dose, ciprofloxacin 33% of dose, and norfloxacin 22% of dose.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),,54,59412,DB00467,Enoxacin
,9624541,total amount,"The total amount (mean) excreted by the kidneys as parent drugs were as follows: enoxacin 54% of dose, ciprofloxacin 33% of dose, and norfloxacin 22% of dose.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),,33,59413,DB00467,Enoxacin
,9624541,plasma concentrations,"The mean plasma concentrations decreased from 1 to 4 h after administration for enoxacin from 1.9 to 1.4 mg/l, for ciprofloxacin from 2.0 to 0.8 mg/l and for norfloxacin from 1.3 to 0.5 mg/l.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],1.9 to 1.4,59414,DB00467,Enoxacin
,2907467,urinary,"The urinary and fecal recoveries of NY-198 were 76.3 +/- 1.3% and 21.0 +/- 0.1% of the dose (mean +/- SE, N = 3), respectively, after the iv administration of [14C]NY-198 as a 20 mg/kg dose.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),%,76.3,59596,DB00467,Enoxacin
,2907467,fecal recoveries,"The urinary and fecal recoveries of NY-198 were 76.3 +/- 1.3% and 21.0 +/- 0.1% of the dose (mean +/- SE, N = 3), respectively, after the iv administration of [14C]NY-198 as a 20 mg/kg dose.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),%,21.0,59597,DB00467,Enoxacin
,2907467,volume of distribution at steady state per body weight (Vdss/BW),Model-independent moment analysis of the serum concentration-time profile of [14C]NY-198 gave the volume of distribution at steady state per body weight (Vdss/BW) as 1150 ml/kg.,"Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg],1150,59598,DB00467,Enoxacin
,2907467,Intrinsic renal clearance (CLint.kd),"Intrinsic renal clearance (CLint.kd) and intrinsic hepatic clearance (CLint.lv) were estimated to be 7.68 ml/min/kg and 6.33 ml/min/kg, respectively, by the cumulative urinary recovery and the area under the curve of the serum concentration-time profile of NY-198 and the blood flow rate.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg·min],7.68,59599,DB00467,Enoxacin
,2907467,intrinsic hepatic clearance (CLint.lv),"Intrinsic renal clearance (CLint.kd) and intrinsic hepatic clearance (CLint.lv) were estimated to be 7.68 ml/min/kg and 6.33 ml/min/kg, respectively, by the cumulative urinary recovery and the area under the curve of the serum concentration-time profile of NY-198 and the blood flow rate.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg·min],6.33,59600,DB00467,Enoxacin
,2907467,Kp,"The Kp values of NY-198 ranged from 0.22 to 4.85 and were very similar to those for ofloxacin, being the highest in the disposing organs, kidneys and liver, the lowest in fat and brain, and modest in the other nondisposing organs.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),,0.22 to 4.85,59601,DB00467,Enoxacin
,1559306,bioavailability,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),%,95 to 100,62035,DB00467,Enoxacin
,1559306,peak serum concentrations,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),[mg] / [l],2 to 3,62036,DB00467,Enoxacin
,1559306,half-life,"The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h.",Ofloxacin clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559306/),h,5 to 8,62037,DB00467,Enoxacin
,6226241,peak plasma levels,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],2.39,63519,DB00467,Enoxacin
,6226241,peak plasma levels,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],1.63,63520,DB00467,Enoxacin
,6226241,peak plasma levels,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],5.00,63521,DB00467,Enoxacin
,6226241,elimination half-lives,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,2.24,63522,DB00467,Enoxacin
,6226241,elimination half-lives,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,2.81,63523,DB00467,Enoxacin
,6226241,elimination half-lives,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,5.76,63524,DB00467,Enoxacin
,6226241,elimination half-lives,"The respective mean plasma levels of norfloxacin at similar dosages were 0.510, 0.410, and 0.700 mug/ml; elimination half-lives were 1.40, 2.35, and 6.06 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,1.40,63525,DB00467,Enoxacin
,6226241,elimination half-lives,"The respective mean plasma levels of norfloxacin at similar dosages were 0.510, 0.410, and 0.700 mug/ml; elimination half-lives were 1.40, 2.35, and 6.06 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,2.35,63526,DB00467,Enoxacin
,6226241,elimination half-lives,"The respective mean plasma levels of norfloxacin at similar dosages were 0.510, 0.410, and 0.700 mug/ml; elimination half-lives were 1.40, 2.35, and 6.06 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,6.06,63527,DB00467,Enoxacin
,6226241,binding rates,"The binding rates of AT-2266 and norfloxacin to plasma of mice, rats, and dogs and to human serum ranged from 27.6 to 40.2% and 39.8 to 44.2%, respectively.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,27.6 to 40.2,63528,DB00467,Enoxacin
,6226241,binding rates,"The binding rates of AT-2266 and norfloxacin to plasma of mice, rats, and dogs and to human serum ranged from 27.6 to 40.2% and 39.8 to 44.2%, respectively.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,39.8 to 44.2,63529,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],2.47,63530,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],4.60,63531,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],5.35,63532,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],33.9,63533,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],0.234,63534,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],0.390,63535,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],0.272,63536,DB00467,Enoxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],2.05,63537,DB00467,Enoxacin
,6226241,24-,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,56.6,63538,DB00467,Enoxacin
,6226241,24-,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,40.5,63539,DB00467,Enoxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,56.6,63540,DB00467,Enoxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,40.5,63541,DB00467,Enoxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,64.1,63542,DB00467,Enoxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,4.40,63543,DB00467,Enoxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,2.91,63544,DB00467,Enoxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,5.34,63545,DB00467,Enoxacin
,6226241,24-h,The respective 24-h recoveries of AT-2266 from bile and feces of rats given a single dose of 50 mg/kg were 2.47 and 52.7%.,"Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,2.47,63546,DB00467,Enoxacin
,6226241,recoveries,The respective 24-h recoveries of AT-2266 from bile and feces of rats given a single dose of 50 mg/kg were 2.47 and 52.7%.,"Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,2.47,63547,DB00467,Enoxacin
,6226241,recoveries,The respective 24-h recoveries of AT-2266 from bile and feces of rats given a single dose of 50 mg/kg were 2.47 and 52.7%.,"Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,52.7,63548,DB00467,Enoxacin
,3282749,bioavaila,"With the exception of norfloxacin, which is only 30 to 40% bioavailable from the oral route, the 4-quinolones are 80 to 100% bioavailable, absorption occurring within 1 to 3 hours.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,80 to 100,67687,DB00467,Enoxacin
greater,3282749,volumes of distribution,"The 4-quinolones are widely distributed throughout the body, with volumes of distribution greater than 1.5 L/kg.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),[l] / [kg],1.5,67688,DB00467,Enoxacin
less,3282749,Protein binding,Protein binding is less than 30% in most cases.,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,30,67689,DB00467,Enoxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,3 and 5,67690,DB00467,Enoxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,8 to 14,67691,DB00467,Enoxacin
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,8.7,70499,DB00467,Enoxacin
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,17.4,70500,DB00467,Enoxacin
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,6.1,70501,DB00467,Enoxacin
,3211700,elimination half-lives,"During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 to 12.3 h, respectively.",The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers. A pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211700/),h,12.3,70502,DB00467,Enoxacin
,3162904,half-life,"The half-life of both enoxacin and 4-oxo-enoxacin was 5-6 h; during treatment with 400 and 600 mg bd, the plasma concentrations exceeded MIC values for most bacteria isolated in respiratory tract infections, including most Pseudomonas aeruginosa strains; Streptococcus pneumoniae was an exception.",Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162904/),h,5-6,77760,DB00467,Enoxacin
,3162904,Diffusion,Diffusion from plasma to sputum was approximately 100%.,Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162904/),%,100,77761,DB00467,Enoxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.2,77966,DB00467,Enoxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.9,77967,DB00467,Enoxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.75,77968,DB00467,Enoxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.9,77969,DB00467,Enoxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,4.0,77970,DB00467,Enoxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,7.0,77971,DB00467,Enoxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,6.2,77972,DB00467,Enoxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,5.1,77973,DB00467,Enoxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,10.5,77974,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,62,77975,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,46.4,77976,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,12.2,77977,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,27,77978,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,30.6,77979,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,75.7,77980,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,73,77981,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,4.9,77982,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,9.2,77983,DB00467,Enoxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,17.8,77984,DB00467,Enoxacin
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],0.1,101755,DB00467,Enoxacin
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],1,101756,DB00467,Enoxacin
exceeded,3116917,peak concentration/MIC ratio,"However, bacterial regrowth occurred within 24 h unless the peak concentration/MIC ratio exceeded 8:1 (P less than 0.01).",Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3116917/),,8:1,106856,DB00467,Enoxacin
,2221856,Total clearance,"Total clearance of enoxacin decreased from 4.95 +/- 1.16 ml/min per kg in the group with normal creatinine clearance to 0.76 +/- 0.21 ml/min per kg in the patients with severe renal failure (creatinine clearance, less than 15 ml/min), whereas the elimination half-life increased from 4.5 +/- 1.0 to 20 +/- 5 h, respectively.",Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2221856/),[ml] / [kg·min],4.95,109674,DB00467,Enoxacin
,2221856,Total clearance,"Total clearance of enoxacin decreased from 4.95 +/- 1.16 ml/min per kg in the group with normal creatinine clearance to 0.76 +/- 0.21 ml/min per kg in the patients with severe renal failure (creatinine clearance, less than 15 ml/min), whereas the elimination half-life increased from 4.5 +/- 1.0 to 20 +/- 5 h, respectively.",Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2221856/),[ml] / [kg·min],0.76,109675,DB00467,Enoxacin
,2221856,elimination half-life,"Total clearance of enoxacin decreased from 4.95 +/- 1.16 ml/min per kg in the group with normal creatinine clearance to 0.76 +/- 0.21 ml/min per kg in the patients with severe renal failure (creatinine clearance, less than 15 ml/min), whereas the elimination half-life increased from 4.5 +/- 1.0 to 20 +/- 5 h, respectively.",Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2221856/),h,4.5,109676,DB00467,Enoxacin
,2221856,elimination half-life,"Total clearance of enoxacin decreased from 4.95 +/- 1.16 ml/min per kg in the group with normal creatinine clearance to 0.76 +/- 0.21 ml/min per kg in the patients with severe renal failure (creatinine clearance, less than 15 ml/min), whereas the elimination half-life increased from 4.5 +/- 1.0 to 20 +/- 5 h, respectively.",Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2221856/),h,20,109677,DB00467,Enoxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],23.0,113561,DB00467,Enoxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],14.4,113562,DB00467,Enoxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.2,113963,DB00467,Enoxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.9,113964,DB00467,Enoxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.75,113965,DB00467,Enoxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.9,113966,DB00467,Enoxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,4.0,113967,DB00467,Enoxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,7.0,113968,DB00467,Enoxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,6.2,113969,DB00467,Enoxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,5.1,113970,DB00467,Enoxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,10.5,113971,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113972,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113973,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113974,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113975,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113976,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113977,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113978,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113979,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113980,DB00467,Enoxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113981,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113982,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113983,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113984,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113985,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113986,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113987,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113988,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113989,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113990,DB00467,Enoxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113991,DB00467,Enoxacin
,2933340,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.03 and 4,121285,DB00467,Enoxacin
,2933340,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except for two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.25 and 16,121286,DB00467,Enoxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.7 and 6.3,121287,DB00467,Enoxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],3.6,121288,DB00467,Enoxacin
,2933340,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),%,31.2,121289,DB00467,Enoxacin
,3129392,peak mouse blood levels,Single oral and subcutaneous enoxacin doses (50 mg/kg) gave peak mouse blood levels of 4.9 and 9.5 mg/l and an elimination half-life of 1.8 h.,Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129392/),[mg] / [l],4.9,137480,DB00467,Enoxacin
,3129392,peak mouse blood levels,Single oral and subcutaneous enoxacin doses (50 mg/kg) gave peak mouse blood levels of 4.9 and 9.5 mg/l and an elimination half-life of 1.8 h.,Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129392/),[mg] / [l],9.5,137481,DB00467,Enoxacin
,3129392,elimination half-life,Single oral and subcutaneous enoxacin doses (50 mg/kg) gave peak mouse blood levels of 4.9 and 9.5 mg/l and an elimination half-life of 1.8 h.,Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129392/),h,1.8,137482,DB00467,Enoxacin
,6389477,minimum concentration,"Steady state was reached in four days or less, with an average minimum concentration of 1.25 mg/l and the average concentration achieved 1.5 h after the dose was 3.53 mg/l.",Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389477/),[mg] / [l],1.25,139315,DB00467,Enoxacin
,6389477,concentration,"Steady state was reached in four days or less, with an average minimum concentration of 1.25 mg/l and the average concentration achieved 1.5 h after the dose was 3.53 mg/l.",Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389477/),,3,139316,DB00467,Enoxacin
,14733712,corneal,Nalidixic acid had a higher corneal permeability coefficient (17.3 +/- 3.56 x 10(-6) cm/second) than all other drugs tested (p < 0.01).,Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [second],17.3,142241,DB00467,Enoxacin
,14733712,permeability coefficient,Nalidixic acid had a higher corneal permeability coefficient (17.3 +/- 3.56 x 10(-6) cm/second) than all other drugs tested (p < 0.01).,Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [second],17.3,142242,DB00467,Enoxacin
,14733712,perme,"Comparing the corneal and scleral permeability coefficients, only values for nalidixic acid were not significantly different (17.35 +/- 3.56 x l0(-6) cm/second versus 22.69 +/- 5.19 x 10(-6) cm/second, p > 0.05), while all other drugs had scleral permeability coefficients 8 to 10 times greater than corneal permeability coefficients.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [(l0)^6·second],17.35,142243,DB00467,Enoxacin
,14733712,perme,"Comparing the corneal and scleral permeability coefficients, only values for nalidixic acid were not significantly different (17.35 +/- 3.56 x l0(-6) cm/second versus 22.69 +/- 5.19 x 10(-6) cm/second, p > 0.05), while all other drugs had scleral permeability coefficients 8 to 10 times greater than corneal permeability coefficients.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),,22.69,142244,DB00467,Enoxacin
,14733712,aqueous humor concentration,"The mean aqueous humor concentration of norfloxacin and ciprofloxacin at 60 minutes to 180 minutes after instillation was around 0.3 microg/mL, a value higher than MIC90 of most bacteria.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[μg] / [ml],0.3,142245,DB00467,Enoxacin
,9691332,Retention times,"Retention times are 5.2 min for enoxacin, 6.8 min for pefloxacin and 12 min for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),min,5.2,154619,DB00467,Enoxacin
,9691332,Retention times,"Retention times are 5.2 min for enoxacin, 6.8 min for pefloxacin and 12 min for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),min,6.8,154620,DB00467,Enoxacin
,9691332,Retention times,"Retention times are 5.2 min for enoxacin, 6.8 min for pefloxacin and 12 min for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),min,12,154621,DB00467,Enoxacin
,9691332,percent recovery,The percent recovery from the nominal values for accuracy ranged from 94 to 108%.,Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),%,94 to 108,154622,DB00467,Enoxacin
,9691332,detection limits,"The detection limits were 10 ng/ml and 25 ng/g, respectively.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),[ng] / [ml],10,154623,DB00467,Enoxacin
,9691332,detection limits,"The detection limits were 10 ng/ml and 25 ng/g, respectively.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),[ng] / [g],25,154624,DB00467,Enoxacin
,9691332,extraction recoveries,"In plasma, the extraction recoveries averaged 52% for enoxacin and 63% for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),%,52,154625,DB00467,Enoxacin
,9691332,extraction recoveries,"In plasma, the extraction recoveries averaged 52% for enoxacin and 63% for 4-oxo-enoxacin.",Reversed-phase high-performance liquid chromatographic determination of enoxacin and 4-oxo-enoxacin in human plasma and prostatic tissue. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691332/),%,63,154626,DB00467,Enoxacin
,3463543,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.03 and 4,159866,DB00467,Enoxacin
,3463543,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.25 and 16,159867,DB00467,Enoxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.7 and 6.3,159868,DB00467,Enoxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],3.6,159869,DB00467,Enoxacin
,3463543,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),%,31.2,159870,DB00467,Enoxacin
,2542469,Metabolism,Metabolism is minimal (ca. 15-20% for ciprofloxacin and norfloxacin).,Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),%,15-20,166231,DB00467,Enoxacin
,2542469,serum half-life,"Because the transintestinal route of elimination compensates for loss of renal elimination, the serum half-life of ciprofloxacvin is raised only to 5-10 hours even in total renal failure.",Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),h,5-10,166232,DB00467,Enoxacin
,3475036,peak bronchial secretion levels,Mean peak bronchial secretion levels were similar for the 400-mg dose schedules (2.2 and 2.4 micrograms/ml) but were significantly higher with the 600-mg dose (4.0 micrograms/ml) (P less than 0.05).,Penetration of enoxacin into bronchial secretions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3475036/),[μg] / [ml],2.2,167316,DB00467,Enoxacin
,3475036,peak bronchial secretion levels,Mean peak bronchial secretion levels were similar for the 400-mg dose schedules (2.2 and 2.4 micrograms/ml) but were significantly higher with the 600-mg dose (4.0 micrograms/ml) (P less than 0.05).,Penetration of enoxacin into bronchial secretions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3475036/),[μg] / [ml],2.4,167317,DB00467,Enoxacin
,3475036,peak bronchial secretion levels,Mean peak bronchial secretion levels were similar for the 400-mg dose schedules (2.2 and 2.4 micrograms/ml) but were significantly higher with the 600-mg dose (4.0 micrograms/ml) (P less than 0.05).,Penetration of enoxacin into bronchial secretions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3475036/),[μg] / [ml],4.0,167318,DB00467,Enoxacin
,3162901,plasma concentrations,"At the end of a 1 h intravenous infusion period, mean enoxacin plasma concentrations were 1.8 and 6.6 mg/l for the 200 and 800 mg doses, respectively.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),[mg] / [l],1.8,169677,DB00467,Enoxacin
,3162901,plasma concentrations,"At the end of a 1 h intravenous infusion period, mean enoxacin plasma concentrations were 1.8 and 6.6 mg/l for the 200 and 800 mg doses, respectively.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),[mg] / [l],6.6,169678,DB00467,Enoxacin
,3162901,elimination half lives,"Disappearance of enoxacin from the systemic circulation appeared to follow first order kinetics with harmonic mean elimination half lives of 3.3 and 4.7 h for the 200 and 800 mg dose groups, respectively.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),h,3.3,169679,DB00467,Enoxacin
,3162901,elimination half lives,"Disappearance of enoxacin from the systemic circulation appeared to follow first order kinetics with harmonic mean elimination half lives of 3.3 and 4.7 h for the 200 and 800 mg dose groups, respectively.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),h,4.7,169680,DB00467,Enoxacin
,3162901,volume of distribution,The volume of distribution was large (2.8 l/kg) and independent of dose.,Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),[l] / [kg],2.8,169681,DB00467,Enoxacin
,3162901,peak plasma concentrations,"Absorption of orally administered enoxacin was rapid, with mean peak plasma concentrations (1.0 and 3.8 mg/l) appearing one to two hours postdose.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),[mg] / [l],1.0,169682,DB00467,Enoxacin
,3162901,peak plasma concentrations,"Absorption of orally administered enoxacin was rapid, with mean peak plasma concentrations (1.0 and 3.8 mg/l) appearing one to two hours postdose.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),[mg] / [l],3.8,169683,DB00467,Enoxacin
,3162901,Absolute oral bioavailability,"Absolute oral bioavailability averaged 89%, and was independent of the dose administered.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),%,89,169684,DB00467,Enoxacin
,3162901,Urinary excretion,"Urinary excretion of the oxo-metabolite averaged 16% and 11% following the 200 and 800 mg dose, respectively.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),%,16,169685,DB00467,Enoxacin
,3162901,Urinary excretion,"Urinary excretion of the oxo-metabolite averaged 16% and 11% following the 200 and 800 mg dose, respectively.",Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162901/),%,11,169686,DB00467,Enoxacin
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.85,172631,DB00467,Enoxacin
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.56,172632,DB00467,Enoxacin
,28756357,flow rate,"After solid phase extraction process using Evolute® ABN 96 fixed well plate; levofloxacin and internal standard-enoxacin were separated using a mobile phase consisting of phosphate buffer 10mM with 0.025% triethylamine pH 3.0 - acetonitrile (88:12, v/v) on a Purosphere RP-8e column (5μm, 125×4.0mm) at a flow rate of 1.2mL/min at 35°C.",High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),[ml] / [min],1.2,180176,DB00467,Enoxacin
,28756357,excitation/emission wavelengths,"The excitation/emission wavelengths were set to 269/400nm and 294/500nm, for enoxacin and levofloxacin, respectively.",High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),nm,269/400,180177,DB00467,Enoxacin
,28756357,excitation/emission wavelengths,"The excitation/emission wavelengths were set to 269/400nm and 294/500nm, for enoxacin and levofloxacin, respectively.",High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),n,294,180178,DB00467,Enoxacin
,28756357,limit of detection,The method was linear over the concentration range of 0.02 to 20.0μg/mL with a limit of detection of 0.01μg/mL.,High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),[μg] / [ml],0.01,180179,DB00467,Enoxacin
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],77.8,180503,DB00467,Enoxacin
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],31.8,180504,DB00467,Enoxacin
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,9.7,180505,DB00467,Enoxacin
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,4.5,180506,DB00467,Enoxacin
,2202843,peak levels,"Mean serum drug concentrations for the 3 dosage groups were at peak levels of 0.27, 0.64 and 1.51 micrograms/ml at 4, 2 and 1 hour(s) after administration, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.27,183350,DB00467,Enoxacin
,2202843,peak levels,"Mean serum drug concentrations for the 3 dosage groups were at peak levels of 0.27, 0.64 and 1.51 micrograms/ml at 4, 2 and 1 hour(s) after administration, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.64,183351,DB00467,Enoxacin
,2202843,peak levels,"Mean serum drug concentrations for the 3 dosage groups were at peak levels of 0.27, 0.64 and 1.51 micrograms/ml at 4, 2 and 1 hour(s) after administration, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],1.51,183352,DB00467,Enoxacin
,2202843,Tmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,3.0,183353,DB00467,Enoxacin
,2202843,Tmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,1.2,183354,DB00467,Enoxacin
,2202843,Cmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.32,183355,DB00467,Enoxacin
,2202843,Cmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.78,183356,DB00467,Enoxacin
,2202843,Cmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],1.56,183357,DB00467,Enoxacin
,2202843,serum half-lives,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,2.2,183358,DB00467,Enoxacin
,2202843,serum half-lives,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,2.4,183359,DB00467,Enoxacin
,2202843,serum half-lives,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,2.3,183360,DB00467,Enoxacin
,2202843,AUCs,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[h·μg] / [ml],1.65,183361,DB00467,Enoxacin
,2202843,AUCs,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[h·μg] / [ml],3.98,183362,DB00467,Enoxacin
,2202843,AUCs,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[h·μg] / [ml],6.06,183363,DB00467,Enoxacin
,2202843,peak urinary drug concentrations,"2. Mean peak urinary drug concentrations for the 3 dosage groups were 45.8, 109.2 and 215.1 micrograms/ml, respectively, and the peaks appeared 2-4 hours after administration.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],45.8,183364,DB00467,Enoxacin
,2202843,peak urinary drug concentrations,"2. Mean peak urinary drug concentrations for the 3 dosage groups were 45.8, 109.2 and 215.1 micrograms/ml, respectively, and the peaks appeared 2-4 hours after administration.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],109.2,183365,DB00467,Enoxacin
,2202843,peak urinary drug concentrations,"2. Mean peak urinary drug concentrations for the 3 dosage groups were 45.8, 109.2 and 215.1 micrograms/ml, respectively, and the peaks appeared 2-4 hours after administration.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],215.1,183366,DB00467,Enoxacin
,2202843,recovery rates,"Mean recovery rates up to 8 hours after administration were 18.3%, 24.5% and 28.7%, respectively for the 3 dosages.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),%,18.3,183367,DB00467,Enoxacin
,2202843,recovery rates,"Mean recovery rates up to 8 hours after administration were 18.3%, 24.5% and 28.7%, respectively for the 3 dosages.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),%,24.5,183368,DB00467,Enoxacin
,2202843,recovery rates,"Mean recovery rates up to 8 hours after administration were 18.3%, 24.5% and 28.7%, respectively for the 3 dosages.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),%,28.7,183369,DB00467,Enoxacin
,2202843,MIC,"3. In a drug sensitivity test against 128 strains of S. sonnei, the most frequent MIC value of NFLX was 0.78 micrograms/ml against 65 strains, followed by 0.39 micrograms/ml for 56 strains.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.78,183370,DB00467,Enoxacin
,2202843,MIC,"3. In a drug sensitivity test against 128 strains of S. sonnei, the most frequent MIC value of NFLX was 0.78 micrograms/ml against 65 strains, followed by 0.39 micrograms/ml for 56 strains.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.39,183371,DB00467,Enoxacin
,2202843,Clinical,4. Clinical efficacy rate of NFLX against bacillary dysentery was 95.2% in 21 cases in which the evaluation was possible.,[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),,95,183372,DB00467,Enoxacin
,2791445,steady-state theophylline concentration,Mean steady-state theophylline concentration in plasma during the dosing interval increased from 3.17 to 8.23 micrograms/ml.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),[μg] / [ml],3.17,189127,DB00467,Enoxacin
,2791445,steady-state theophylline concentration,Mean steady-state theophylline concentration in plasma during the dosing interval increased from 3.17 to 8.23 micrograms/ml.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),[μg] / [ml],8.23,189128,DB00467,Enoxacin
,2791445,12-hour,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,76.3,189129,DB00467,Enoxacin
,2791445,12-hour,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,38.6,189130,DB00467,Enoxacin
,2791445,recovery,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,76.3,189131,DB00467,Enoxacin
,2791445,recovery,The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg.,The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791445/),mg,38.6,189132,DB00467,Enoxacin
,2920479,bioavailability,"Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%.",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),%,100,197116,DB00467,Enoxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],1.5,197117,DB00467,Enoxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],10.7,197118,DB00467,Enoxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],78,197119,DB00467,Enoxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],5.5,197120,DB00467,Enoxacin
,2920479,apparent volume of distribution,Protein binding is low (less than or equal to 30%) and apparent volume of distribution is between 1.5 and 3.1 liters/kg.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[l] / [kg],1.5 and 3.1,197121,DB00467,Enoxacin
,2920479,half-lives,"Norfloxacin and ciprofloxacin have the shortest half-lives (+/- 4h), while fleroxacin and pefloxacin have the longest (10-12h).",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),h,10-12,197122,DB00467,Enoxacin
greater,7735486,resolution factor,The peaks with a resolution factor greater than 1.5 were free from interferences.,Sensitive high-performance liquid chromatographic assay for norfloxacin utilizing fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735486/),,1.5,200138,DB00467,Enoxacin
,6591851,peak levels,"Absorption was variable, with peak levels (mean, 3.7 micrograms/ml) being attained between 0.75 and 3.0 h (mean, 1.9 h).",Pharmacokinetics and tissue penetration of enoxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6591851/),[μg] / [ml],3.7,201284,DB00467,Enoxacin
,6591851,serum elimination half-life,"The serum elimination half-life was 6.2 h, and 71.6% of the drug was recovered in the urine by 48 h.",Pharmacokinetics and tissue penetration of enoxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6591851/),h,6.2,201285,DB00467,Enoxacin
,6591851,percent penetration,"Enoxacin penetrated blister fluid well, the mean percent penetration being 78.4%.",Pharmacokinetics and tissue penetration of enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6591851/),%,78.4,201286,DB00467,Enoxacin
,6583207,minimum detectable concentrations,"The minimum detectable concentrations of AT-2266 in plasma and urine are 0.01 micrograms/ml and 0.1 micrograms/ml, respectively, and those of other metabolites are similar to those of AT-2266.",Determination of a new antibacterial agent (AT-2266) and its metabolites in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583207/),[μg] / [ml],0.01,203100,DB00467,Enoxacin
,6583207,minimum detectable concentrations,"The minimum detectable concentrations of AT-2266 in plasma and urine are 0.01 micrograms/ml and 0.1 micrograms/ml, respectively, and those of other metabolites are similar to those of AT-2266.",Determination of a new antibacterial agent (AT-2266) and its metabolites in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583207/),[μg] / [ml],0.1,203101,DB00467,Enoxacin
,8494374,nonrenal clearance,The mean nonrenal clearance increased from 13.27 +/- 3.33 to 15.68 +/- 2.35 liters/h (18.2%) following the antacid regimen.,Effect of oral antacids on disposition of intravenous enoxacin. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494374/),[l] / [h],13.27,209158,DB00467,Enoxacin
,8494374,nonrenal clearance,The mean nonrenal clearance increased from 13.27 +/- 3.33 to 15.68 +/- 2.35 liters/h (18.2%) following the antacid regimen.,Effect of oral antacids on disposition of intravenous enoxacin. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494374/),[l] / [h],15.68,209159,DB00467,Enoxacin
,7855046,steady state plasma concentrations,"The effects of two fluoroquinolones, enoxacin (ENOX) and ciprofloxacin (CIPRO), have been studied in male Sprague-Dawley rats (n = 33-46) at steady state plasma concentrations of 0-33 mg.l-1, achieved by supplementing an intravenous bolus dose with a constant rate infusion.",Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7855046/),[mg] / [l],0-33,215443,DB00467,Enoxacin
,15905806,Cmax,"Enoxacin significantly increased the plasma concentrations at 2 hours (placebo versus enoxacin, mean+/-SD: 4.4+/-2.4 vs 7.0+/-4.1 ng/mL, P<0.05) and 3 hours (7.4+/-2.7 vs 11.2+/-3.8 ng/mL, P<0.01) and the Cmax (10.2+/-2.9 vs 11.6+/-4.0 ng/mL, P<0.05) of FLV.",Interaction study between enoxacin and fluvoxamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905806/),[ng] / [ml],10.2,222246,DB00467,Enoxacin
,15905806,Cmax,"Enoxacin significantly increased the plasma concentrations at 2 hours (placebo versus enoxacin, mean+/-SD: 4.4+/-2.4 vs 7.0+/-4.1 ng/mL, P<0.05) and 3 hours (7.4+/-2.7 vs 11.2+/-3.8 ng/mL, P<0.01) and the Cmax (10.2+/-2.9 vs 11.6+/-4.0 ng/mL, P<0.05) of FLV.",Interaction study between enoxacin and fluvoxamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905806/),[ng] / [ml],11.6,222247,DB00467,Enoxacin
,1667252,peak concentration,"After oral administration of NM441 at a dose of 20 mg/kg to dogs, the peak concentration of NM394 in plasma was 2.39 micrograms/ml, whereas it was 0.63 micrograms/ml for NM394 administered alone.","In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1667252/),[μg] / [ml],2.39,235216,DB00467,Enoxacin
,1667252,peak concentration,"After oral administration of NM441 at a dose of 20 mg/kg to dogs, the peak concentration of NM394 in plasma was 2.39 micrograms/ml, whereas it was 0.63 micrograms/ml for NM394 administered alone.","In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1667252/),[μg] / [ml],0.63,235217,DB00467,Enoxacin
,2291662,peak enoxacin concentrations,"Average peak enoxacin concentrations following i.v. and oral dosing were 8.15 and 5.45 mg/liter, respectively.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[mg] / [l],8.15,241090,DB00467,Enoxacin
,2291662,peak enoxacin concentrations,"Average peak enoxacin concentrations following i.v. and oral dosing were 8.15 and 5.45 mg/liter, respectively.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[mg] / [l],5.45,241091,DB00467,Enoxacin
,2291662,area under the concentration-time curve from 0 to 12 h,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[h·mg] / [l],47.6,241092,DB00467,Enoxacin
,2291662,area under the concentration-time curve from 0 to 12 h,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[h·mg] / [l],41.0,241093,DB00467,Enoxacin
,2291662,volume of distribution,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[l] / [kg],1.61,241094,DB00467,Enoxacin
,2291662,volume of distribution/bioavailability,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[l] / [kg],1.61,241095,DB00467,Enoxacin
,2291662,volume of distribution/bioavailability,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[l] / [kg],1.99,241096,DB00467,Enoxacin
,2291662,total body clearance,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[ml] / [kg·min],2.58,241097,DB00467,Enoxacin
,2291662,total body clearance/bioavailability,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[ml] / [kg·min],2.58,241098,DB00467,Enoxacin
,2291662,total body clearance/bioavailability,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),[ml] / [kg·min],3.01,241099,DB00467,Enoxacin
,2291662,half-life,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),h,8.2,241100,DB00467,Enoxacin
,2291662,half-life,"Mean values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0 mg.h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),h,9.1,241101,DB00467,Enoxacin
,2291662,bioavailable,"Enoxacin was highly bioavailable (mean, 86.97%) following oral administration.",Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291662/),%,86.97,241102,DB00467,Enoxacin
,3162906,Plasma half-life,"Plasma half-life (10.6-11.6 h) in volunteers with severe renal impairment was approximately double the 5.2 h half-life found in subjects with normal renal function, and this should result in steady-state enoxacin concentrations approximately double those measured in normal subjects given equivalent doses.",The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162906/),h,10.6-11.6,252268,DB00467,Enoxacin
,3162906,Plasma half-life,"Plasma half-life (10.6-11.6 h) in volunteers with severe renal impairment was approximately double the 5.2 h half-life found in subjects with normal renal function, and this should result in steady-state enoxacin concentrations approximately double those measured in normal subjects given equivalent doses.",The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162906/),h,5.2,252269,DB00467,Enoxacin
,3162906,half,"Plasma half-life (10.6-11.6 h) in volunteers with severe renal impairment was approximately double the 5.2 h half-life found in subjects with normal renal function, and this should result in steady-state enoxacin concentrations approximately double those measured in normal subjects given equivalent doses.",The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162906/),h,5.2,252270,DB00467,Enoxacin
,3553134,peak enoxacin serum concentrations,"Mean peak enoxacin serum concentrations in nonfasted CF-1 mice following a single 50, 100, or 200 mg/kg oral dose were 2.0, 4.0 and 11.4 mg/l, respectively, with proportional increases in area under the serum concentration curves.",Enoxacin pharmacokinetics and efficacy in CF-1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3553134/),[mg] / [l],2.0,259628,DB00467,Enoxacin
,3553134,peak enoxacin serum concentrations,"Mean peak enoxacin serum concentrations in nonfasted CF-1 mice following a single 50, 100, or 200 mg/kg oral dose were 2.0, 4.0 and 11.4 mg/l, respectively, with proportional increases in area under the serum concentration curves.",Enoxacin pharmacokinetics and efficacy in CF-1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3553134/),[mg] / [l],4.0,259629,DB00467,Enoxacin
,3553134,peak enoxacin serum concentrations,"Mean peak enoxacin serum concentrations in nonfasted CF-1 mice following a single 50, 100, or 200 mg/kg oral dose were 2.0, 4.0 and 11.4 mg/l, respectively, with proportional increases in area under the serum concentration curves.",Enoxacin pharmacokinetics and efficacy in CF-1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3553134/),[mg] / [l],11.4,259630,DB00467,Enoxacin
,11102420,elimination half-lives,"On the first day of treatment, elimination half-lives were 6.8 h for enoxacin and 7.1 h for its metabolite; they were increased on day 4 (10.3 and 13.2 h, respectively).",Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11102420/),h,6.8,260036,DB00467,Enoxacin
,11102420,elimination half-lives,"On the first day of treatment, elimination half-lives were 6.8 h for enoxacin and 7.1 h for its metabolite; they were increased on day 4 (10.3 and 13.2 h, respectively).",Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11102420/),h,7.1,260037,DB00467,Enoxacin
,11102420,elimination half-lives,"On the first day of treatment, elimination half-lives were 6.8 h for enoxacin and 7.1 h for its metabolite; they were increased on day 4 (10.3 and 13.2 h, respectively).",Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11102420/),h,10.3,260038,DB00467,Enoxacin
,11102420,elimination half-lives,"On the first day of treatment, elimination half-lives were 6.8 h for enoxacin and 7.1 h for its metabolite; they were increased on day 4 (10.3 and 13.2 h, respectively).",Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11102420/),h,13.2,260039,DB00467,Enoxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],3.19 x 10(4),263673,DB00467,Enoxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],1.21 x 10(5),263674,DB00467,Enoxacin
,3463542,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax 1.2 h) and enoxacin the least (Tmax 1.9 h).,The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,1.2,271330,DB00467,Enoxacin
,3463542,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax 1.2 h) and enoxacin the least (Tmax 1.9 h).,The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,1.9,271331,DB00467,Enoxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,3.75,271332,DB00467,Enoxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,3.9,271333,DB00467,Enoxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,4.0,271334,DB00467,Enoxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,7.0,271335,DB00467,Enoxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,6.2,271336,DB00467,Enoxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,5.1,271337,DB00467,Enoxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,62,271338,DB00467,Enoxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,46.4,271339,DB00467,Enoxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,11.6,271340,DB00467,Enoxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,27,271341,DB00467,Enoxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,30.6,271342,DB00467,Enoxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,75.7,271343,DB00467,Enoxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,73,271344,DB00467,Enoxacin
